cronos group glp-1 receptor agonists weight management diabetes treatments agonist Frontiers Oral GLP-1-Based Therapeutics in the

Intrapyloric injection of botulinum toxin is not recommended for patients with gastroparesis based on randomized controlled trials

2026 DMEPOS Series #5: Immunosuppressive Drugs for Transplant - June 18, 2026 2026 DMEPOS Series #4: Continuous Glucose Monitors - May 6, 2026 Advance Beneficiary Notice of Noncoverage What You Need to Know - May 4, 2026

nonetheless, it is recommended that careful monitoring be performed

Recently, GLP-1RAs have been approved for the treatment of obesity and recognized for their cardioprotective effects

Generally, weight reduction is more rapid during the first 6 months and slows thereafter, with relative plateauing at 18 months [13,15,16]